FountainTx

Co-Founder and Director of Biology, Joseph Rodgers, Ph.D., will join a panel of fellow industry experts to discuss the ins and outs of building a successful longevity company at the 2022 Longevity Summit. Learn more details here: longevitysummit.io #LongevitySummit

Today, our Co-founder and Executive Chairman Dr. Thomas Rando is being honored in a ceremony held in Zurich to receive the NOMIS Distinguished Scientist Award. Congratulations, Tom! Read more: globenewswire.com/news-release/2…

Please extend a warm welcome to the newest member of the Fountain Therapeutics team Will Shainin, Machine Learning Engineer! We are excited to have Will join our dynamic team.

Please join us in welcoming Lynn Yamamoto, Ph.D., as Director of Translational Biology! We look forward to utilizing Lynn’s expertise as we continue to advance our pipeline of disease-modifying therapeutics.

Our Co-founder and Director of Biology, Joe Rodgers, Ph.D. will be presenting at this year’s Annual Longevity Therapeutics Summit! Tune in to hear him discuss the use of #AI in drug discovery & development for diseases of aging: bit.ly/3mhPGnB

Are you team passionate for innovation, technology and aging research? Then you should consider joining our team. Browse current opportunities here: bit.ly/3wqaZHo

Join us at this year’s @IAmBiotech International Convention in San Diego, CA. We look forward to connecting with our #Biotech peers and exploring potential opportunities with new partners. Learn more here: bit.ly/3wPO2hI #Bio2022

Meet Fernando Martinez, Ph.D., one of our many talented scientists here at Fountain! Fernando’s valuable contributions help advance our drug discovery technology for degenerative diseases. Learn more about our team here: bit.ly/3wqaZHo

Our AI-driven platform combines research and computation to identify novel drug targets to treat chronic #DegenerativeDiseases associated with aging. Learn more about our platform and our unbiased approach to understand the cellular aging process: bit.ly/3wqaZHo

Meet Raj Bhatnagar, Ph.D., one of our many talented scientists helping further our efforts to reverse #CellularAging and build a new way to treat #DegenerativeDiseases. Learn more about our team here: bit.ly/3wqaZHo

Interested in joining a community of ambitious scientists, engineers, and entrepreneurs? Take a look at current opportunities to join our team here: bit.ly/3wqaZHo

We are participating at this year’s 20th Bay Area Aging Meeting. Join us and experts in the aging field to stimulate the advancement of aging research and promote its application to human health. Learn more here: bit.ly/37UiPS7

Our Co-Founder Dr. Thomas Rando will be participating in a keynote panel on regenerative and longevity #research at the @longevityleader world congress. Learn more about here: bit.ly/37i38UH #longevityleaders

Join our CBO @anuhoey and Co-Founder Dr. Thomas Rando at this year’s @longevityleader in-person world congress to advance aging science, regenerative medicine and longevity therapeutics. Learn more here: bit.ly/3DlJTVC #LongevityLeaders

Aging is a predominant challenge to health & quality of life. Using our expertise in #CellularAging our platform combines research & computation with the aim to develop therapeutics to treat chronic #DegenerativeDiseases associated with aging. Learn more: bit.ly/3NtOUjP

Our CEO Dr. William Greene spoke with @Pharmashot to discuss the most recent Series A-2 financing, the company’s approach, motivation & mission develop treatments to extend the healthspan of people living with #ChronicDegenerativeDiseases. Read more here: bit.ly/37LKPHs

Meet one of our many talented scientists, Dr. Anne Pipathsouk. Anne is helping Fountain to develop potential therapeutics for chronic #degenerative diseases by studying #CellularAging with our AI-based platform technology.

#DYK the risk of chronic diseases increases with age? At Fountain, we are dedicated to building a pipeline of therapeutics to help people living with chronic #degenerative diseases. Learn more about aging and chronic health conditions from @agingstats: bit.ly/34fe4jQ

Our platform uses an unbiased approach to understand the cellular aging process. This allows us to identify novel drug targets to treat chronic degenerative diseases. Learn more about our platform that combines aging research and computation here: bit.ly/3KSN5eN

Our CEO Dr. William Greene was featured in this @PharmaScrip article (subscribers only) on the future of #biopharma in 2022 where he discusses using #AI and #MachineLearning in #DrugDiscovery. Read more here: bit.ly/3sCL2oo